Dixon
2010 S58
Strangfel d 2010 S59
Askling
2009 S60
Pallavicin i 2010 S61
Wolfe
2007 S62
Setoguch i 2006 S63
Geborek
2005 S64
Raascho u 2013 S55
Thyagara jan
2012 S16
Ventura-
Ríos
2012 S18
Mercer
2012 S56
Koike
2011 S24
Slimani
2011 S57
Article Country Main Comparator Outcome Finding
UK Etanercept
New- user design
No
Activecompar ator design
Yes Morgan
2014 S53
Solomon
2014 S54
USA TNF inhibitors,
Traditional DMARDs,
Rituximab, Abatacept
Sweden TNF inhibitors
USA Adalimumab
Traditional DMARDs Long-term safety including cancer
Cancer
No elevated risk of malignancy was found.
Methotrexate Reduced cancer risk was observed among TNF inhibitors and Traditional bDMARDs compared to methotrexate.
Traditional DMARDs Invasive melanoma 50% increase risk of invasive melanoma was observed.
Etanercept, Infliximab Fatal infections
(secondary)
Rates of fatal infections were similar among three agents.
No
No
Yes
Yes
Yes
Yes
Mexico
UK
Japan
France
Biological DMARDs
TNF inhibitors
Tocilizumab
Rituximab
UK TNF inhibitors with prior malignancy
Germany Biological DMARDs with prior malignancy
Sweeden TNF inhibitors
Italy
USA
TNF inhibitors
TNF inhibitors
USA,
Canada
TNF inhibitors
Sweeden TNF inhibitors
Traditional DMARDs
Traditional DMARDs
-
-
Traditional DMARDs with prior malignancy
Traditional DMARDs with prior malignancy
Traditional DMARDs
-
Traditional DMARDs or none
Methotrexate
Traditional DMARDs
Safety including infections
Keratinocyte skin cancer
Safety including infections
Cancer
Cancer
Recurrent cancer
Cancer
Cancer
Lymphoma
Malignancies
Malignancies
Higher infection risk than traditional bDMARDs.
Risk was not elevated compared to Traditional bDMARDs.
Most frequent serious adverse events were infections.
Overall cancer rate was comparable to historical
Traditional DMARD cohorts.
Among the selected population studied, no increased risk was observed.
No increased risk was observed.
No elevated risk of malignancy was found.
No elevated risk for overall cancer was found, however, lymphoma risk was elevated.
No increased risk was observed.
No elevated risk of malignancy was found.
No elevated risk for overall cancer was found, however, lymphoma risk was elevated.
No
No
Yes
Yes
No
Yes
Yes
No
No
Yes
No
Yes
No
No
No
Yes
Yes
Yes
No
Yes
Yes
Yes
- 1 -

:
S16.Thyagarajan, V., Norman, H., Alexander, K. A., Napalkov, P. & Enger, C. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients. Semin Arthritis Rheum 42, 223–233 (2012).
S18.Ventura-Rios, L. et al.
Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0. Reumatol Clin 8, 189–
194 (2012).
S24.Koike, T. et al.
Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 70, 2148–
2151 (2011).
S53.Morgan, C. L. et al.
Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology (Oxford) 53, 186–194 (2014).
S54.Solomon, D. H. et al.
Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin
Arthritis Rheum 43, 489–497 (2014).
S55.Raaschou, P., Simard, J. F., Holmqvist, M. & Askling, J. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ 346, (2013).
S56.Mercer, L. K. et al.
The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 71, 869–874 (2012).
S57.Slimani, S., Lukas, C., Combe, B. & Morel, J. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine
78, 484–487 (2011).
S58.Dixon, W. G. et al.
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 62, 755–763 (2010).
S59.Strangfeld, A. et al.
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12, (2010).
S60.Askling, J. et al.
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 60, 3180–3189 (2009).
S61.Pallavicini, F. B. et al.
Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9, 175–180
(2010).
S62.Wolfe, F. & Michaud, K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56, 1433–1439 (2007).
S63.Setoguchi, S. et al.
Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54, 2757–2764 (2006).
S64.Geborek, P. et al.
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64, (2005).
- 2 -